MedTech Terms
    The authoritative reference
    All terms
    Market SegmentsStrategic Landscape

    Cardiovascular Devices

    Devices for diagnosing, monitoring, or treating cardiovascular disease.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Spans structural heart (TAVR, mitral, tricuspid), electrophysiology (ablation, mapping, leadless pacing), interventional (stents, IVUS, OCT), and rhythm management (CRT, ICDs, monitors).
    What the regulation says
    Cardiovascular devices, as medical devices, fall under comprehensive regulatory scrutiny, including FDA Premarket Approval (PMA) or 510(k) clearance in the United States and CE marking under the EU Medical Device Regulation (EU MDR) 2017/745 in Europe. These devices are classified based on their risk to patients, which dictates the strictness of regulatory requirements, such as those outlined in 21 CFR Part 820 for Quality System Regulation.

    What this means in practice

    One of the largest, most R&D-intensive MedTech segments; long evidence cycles and dominant strategics shape competitive dynamics.

    Examples

    • A manufacturer developing a new coronary stent must conduct extensive biocompatibility testing and clinical trials to demonstrate safety and efficacy, fulfilling requirements for a Class III device under the EU MDR.
    • A company designing a pacemaker needs to implement stringent software validation and cybersecurity controls to meet FDA guidance on cybersecurity for medical devices, given its potential for severe patient harm if compromised.
    • A firm producing an ECG analysis algorithm must classify its software as a medical device and ensure its performance claims are clinically validated, in accordance with FDA guidance for Software as a Medical Device.
    Common pitfalls
    • •A common pitfall is inaccurately classifying a cardiovascular device, leading to submission of inadequate regulatory documentation or an inappropriate regulatory pathway.
    • •Manufacturers often underestimate the necessary clinical evidence and long-term follow-up studies required for high-risk cardiovascular devices, causing delays in market authorization.
    • •Failing to adequately address cybersecurity risks for connected cardiovascular devices, such as pacemakers or defibrillators, can lead to significant safety vulnerabilities and regulatory non-compliance.
    • •Ignoring post-market surveillance requirements for cardiovascular devices can result in missed opportunities to identify safety issues and fulfill ongoing regulatory obligations.
    • •Incorrectly defining the device’s intended use can lead to regulatory challenges and limit market access, especially for innovative cardiovascular technologies.

    Frequently asked questions

    Novel cardiovascular implants typically require a Premarket Approval (PMA) in the United States, which involves a rigorous review of clinical data and manufacturing controls. In the EU, they fall under the highest risk classes (e.g., Class III) and necessitate extensive clinical evaluation and notified body review under the EU MDR.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    American College of Cardiology·1AdvaMed·1MedTech Europe·1
    1. 1
      ACC
      Verified
      American College of Cardiologyacc.org
    2. 2
      AdvaMed - Industry Reports
      Verified
      AdvaMedadvamed.org
    3. 3
      MedTech Europe - Facts & Figures
      Verified
      MedTech Europemedtecheurope.org

    Inline markers like [1] jump to the matching reference above.